Overexpression of extracellular-signal regulated kinases on oral squamous cell carcinoma

Oral Oncology

Volumn 38, Issue 5, 2002, Pages 468-474

  Mishima, Kenji ^a   Inoue, Kazuya ^b   Hayashi, Yoshio ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cell proliferation; ERKs; Oral cancer; Signaling proteins; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; MITOGEN ACTIVATED PROTEIN KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN;

CANCER GROWTH; CANCER RESEARCH; CANCER THERAPY; CELL DEATH; CELL LINE; ENZYME ACTIVATION; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SQUAMOUS CELL CARCINOMA;

EID: 0036314050     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(01)00104-X     Document Type: Short Survey

References (123)

1. Head and neck cancer
2. Tobacco and alcohol and the risk of head and neck cancer
3. Epstein-Barr virus in the proliferative diseases of squamous epithelium in the oral cavity
4. In vitro and animal studies of the role of viruses in oral carcinogenesis
5. Cultural and dietary risk factors of oral cancer and precancer - A brief overview
6. Detection of human papillomavirus DNA sequences in oral squamous cell carcinomas and their relation to p53 and proliferating cell nuclear antigen expression
7. Field cancerisation of the oral cavity: Comparison of the spectrum of molecular alterations in cases presenting with both dysplastic and malignant lesions
8. Alterations of p53, cyclin D1, Rb, and H-ras in human oral carcinomas related to tobacco use
9. New insights into the control of MAP kinase pathways
10. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells
11. ERKs: A family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF
12. The mitogen-activated protein kinase signal transduction pathway
13. Survival factors, intracellular signal transduction, and the activation of endonucleases in apoptosis
14. Regulation of transcription by MAP kinase cascades
15. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation
16. Mitogenic signaling via G protein-coupled receptors
17. Transcriptional regulation by extracellular signals: Mechanisms and specificity
18. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase
19. How MAP kinases are regulated
20. The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades
21. Differential amplification of the TGF-alpha gene in human gliomas
22. Growth factor profiles of human gliomas. Do non-tumour cells contribute to tumour growth in glioma?
23. Molecular biology of esophageal cancer
24. Role of tyrosine specific phosphorylation of cellular proteins, especially EGF receptor and p125FAK in human lung cancer cells
25. Expression of the ErbB family of receptors in ovarian cancer
26. Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines
27. Expression of HER2/neu in primary and metastatic breast cancer
28. Overexpression of HER-2 in ovarian carcinomas
29. HER-2/neu amplification and overexpression in endometrial carcinoma
30. Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: Evidence for multistep carcinogenesis
31. Molecular pattern of ductal pancreatic cancer
32. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors
33. Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue
34. Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer
35. Protein kinase C in human renal cell carcinomas: Role in invasion and differential isoenzyme expression
36. Protein kinase C delta involvement in mammary tumor cell metastasis
37. Increased MAPK expression and activity in primary human hepatocellular carcinoma
38. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma
39. Increased MAPK activity and MKP-1 overexpression in human gastric adenocarcinoma
40. Mitogen-activated protein kinases and apoptosis in PIN
41. Expression of keratinocyte growth factor receptor compared with that of epidermal growth factor receptor and erbB-2 in endometrial adenocarcinoma
42. C-erbB-2 gene amplification in nasopharyngeal carcinoma
43. C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer
44. Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma
45. Overexpression of c-Met/hepatocyte growth factor receptors in human prostatic adenocarcinoma
46. Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumor necrosis factor alpha in epithelial ovarian cancer
47. Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues
48. Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas
49. Overexpression of keratinocyte growth factor in cancer cells and enterochromaffin cells in human colorectal cancer
50. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage
51. H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers
52. Ras oncogenes in human cancer: A review
53. K-ras mutation: Early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers - A review
54. Function and regulation of ras
55. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway
56. Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation
57. Cell cycle reentry of mammalian fibroblasts is accompanied by the sustained activation of p44mapk and p42mapk isoforms in the G1 phase and their inactivation at the G1/S transition
58. Mitogen-activated protein kinase/extracellular signal-regulated protein kinase activation by oncogenes, serum, and 12-O-tetradecanoylphorbol-13- acetate requires Raf and is necessary for transformation
59. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells
60. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma
61. H-ras oncogene mutation and human papillomavirus infection in oral carcinomas
62. Ras mutations in United Kingdom examples of oral malignancies are infrequent
63. Ras gene mutations in oral cancer in eastern India
64. The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous-cell carcinoma
65. Alterations of tumor suppressor genes and the H-ras oncogene in oral squamous cell carcinoma
66. Ras gene point mutation is a rare event in premalignant tissues and malignant cells and tissues from oral mucosal lesions
67. Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion
68. Alterations of p16/CDKN2, p53 and ras genes in oral squamous cell carcinomas and premalignant lesions
69. Mutations of Ki-ras oncogene codon 12 in betel quid chewing-related human oral squamous cell carcinoma in Taiwan
70. Expression of epidermal growth factor receptor on oral squamous cell carcinoma
71. Clinical relevance of erbB-1 and-2 oncogenes in oral carcinomas
72. The erbB oncogenes as prognostic markers in oral squamous cell carcinomas
73. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma
74. Amplification and overexpression of epidermal growth factor receptor gene in human oropharyngeal cancer
75. Oral cancer progression and c-erbB-2/neu proto-oncogene expression
76. Overexpression of scatter factor and its receptor (c-met) in oral squamous cell carcinoma
77. Immunohistochemical analysis of the oncoprotein c-erbB-2 expression in oral benign and malignant lesions
78. Immunohistochemical localization of c-myc oncogene product and EGF receptor in oral squamous cell carcinoma
79. Overexpression of the ERK/MAP kinases in oral squamous cell carcinoma
80. Ras-independent activation of the Raf/MEK/ERK pathway upon calcium-induced differentiation of keratinocytes
81. Expression of cyclin dependent kinase inhibitor p21waf1/cip1 in premalignant and malignant oral lesions: Relationship with p53 status
82. An overview of the cell cycle arrest protein, p21(WAF1)
83. Expression of p21/waf1 in oral squamous cell carcinomas - Correlation with p53 and mdm2 and cellular proliferation index
84. Selective interaction of JNK protein kinase isoforms with transcription factors
85. Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun
86. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms
87. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis
88. The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation
89. Molecular cloning and characterization of a human protein kinase that specifically activates c-Jun N-terminal kinase
90. Nuclear accumulation of NFAT4 opposed by the JNK signal transduction pathway
91. Defective T cell differentiation in the absence of Jnk1
92. JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development
93. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene
94. Role of apoptosis signal-regulating kinase in regulation of the c-Jun N-terminal kinase pathway and apoptosis in sympathetic neurons
95. Expression of c-fos, c-jun, and c-jun N-terminal kinase (JNK) in a developmental model of induced apoptotic death in neurons of the substantia nigra
96. Jun N-terminal kinase 2 modulates thymocyte apoptosis and T cell activation through c-Jun and nuclear factor of activated T cell (NF-AT)
97. C-Jun NH2-terminal kinase-mediated activation of interleukin-1beta converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis
98. Cisplatin induces a persistent activation of JNK that is related to cell death
99. Enhancement of chemotherapeutic agents induced-apoptosis associated with activation of c-Jun N-terminal kinase 1 and caspase 3 (CPP32) in bax-transfected gastric cancer cells
100. Evidence that the apoptotic actions of etoposide are independent of c-Jun/activating protein-1-mediated transregulation
101. Activation of SAPK/JNK by camptothecin sensitizes androgen-independent prostate cancer cells to Fas-induced apoptosis
102. Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK)
103. CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin
104. Identification of MAPKAP kinase 2 as a major enzyme responsible for the phosphorylation of the small mammalian heat shock proteins
105. Identification of mitogen-activated protein (MAP) kinase-activated protein kinase-3, a novel substrate of CSBP p38 MAP kinase
106. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2
107. MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates
108. MAPKAPK5, a novel mitogen-activated protein kinase (MAPK)-activated protein kinase, is a substrate of the extracellular-regulated kinase (ERK) and p38 kinase
109. PRAK, a novel protein kinase regulated by the p38 MAP kinase
110. Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB
111. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways
112. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis
113. Pro-inflammatory cytokines and environmental stress cause p38 mitogen- activated protein kinase activation by dual phosphorylation on tyrosine and threonine
114. Stimulation of "stress-regulated" mitogen-activated protein kinases (stress-activated protein kinases/c-Jun N-terminal kinases and p38- mitogen-activated protein kinases) in perfused rat hearts by oxidative and other stresses
115. Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase
116. Constitutively active mitogen-activated protein kinase kinase 6 (MKK6) or salicylate induces spontaneous 3T3-L1 adipogenesis
117. P38 mitogen-activated protein kinase pathway promotes skeletal muscle differentiation. Participation of the Mef2c transcription factor
118. Requirement of p38 mitogen-activated protein kinase for neuronal differentiation in PC12 cells
119. Apoptosis signal-regulating kinase 1 (ASK1) is an intracellular inducer of keratinocyte differentiation
120. Induction of cyclooxygenase-2 by the activated MEKK1 → SEK1/MKK4 → p38 mitogen-activated protein kinase pathway
121. Regulation of cyclooxygenase-2 by interferon gamma and transforming growth factor alpha in normal human epidermal keratinocytes and squamous carcinoma cells. Role of mitogen-activated protein kinases
122. Inhibition of prostaglandin endoperoxide synthase-2 expression in stimulated human monocytes by inhibitors of p38 mitogen-activated protein kinase
123. Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: Regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels